Deep Medicine Acquisition announced today that on Dec. 2 the SPAC’s units will no longer trade, as shares and rights will begin trading separately. Common stock and rights will be listed on the Nasdaq under DMAQ and DMAQR. This is a mandatory and automatic separation, and no action is required by the shareholders, Dep Medicine said in a news release.
Each unit consists of one share of Class A common stock and one right to receive one-tenth of one share.
Purchases of units that are made after the market close today may not settle prior to the unit separation date and, accordingly, the number of rights issued to such purchasers may not reflect the rights underlying recently purchased units.
Deep Medicine Acquisition is focused on targets in the healthcare industry with an enterprise value of approximately $500 million to $1 billion. Read more.
